Use este identificador para citar ou linkar para este item:
http://hdl.handle.net/11690/1899
Registro completo de metadados
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Cavalcanti, Alexandre B. | - |
dc.contributor.author | Zampieri, Fernando G. | - |
dc.contributor.author | Rosa, Regis G. | - |
dc.contributor.author | Azevedo, Luciano C. P. | - |
dc.contributor.author | Veiga, Viviane C. | - |
dc.contributor.author | Avezum, Alvaro | - |
dc.contributor.author | Damiani, Lucas P. | - |
dc.contributor.author | Marcadenti, Aline | - |
dc.contributor.author | Kawano-Dourado, Letícia | - |
dc.contributor.author | Lisboa, Thiago | - |
dc.contributor.author | Junqueira, Debora L. M. | - |
dc.contributor.author | Silva, Pedro G. M. de Barros E | - |
dc.contributor.author | Tramujas, Lucas | - |
dc.contributor.author | Abreu-Silva, Erlon O. | - |
dc.contributor.author | Laranjeira, Ligia N. | - |
dc.contributor.author | Soares, Aline T. | - |
dc.contributor.author | Echenique, Leandro S. | - |
dc.contributor.author | Pereira, Adriano J. | - |
dc.contributor.author | Freitas, Flávio G. R. | - |
dc.contributor.author | Gebara, Otávio C. E. | - |
dc.contributor.author | Dantas, Vicente C. S. | - |
dc.contributor.author | Furtado, Remo H. M. | - |
dc.contributor.author | Milan, Eveline P. | - |
dc.contributor.author | Golin, Nicole A. | - |
dc.contributor.author | Cardoso, Fábio F. | - |
dc.contributor.author | Maia, Israel S. | - |
dc.contributor.author | Hoffmann Filho, Conrado R. | - |
dc.contributor.author | Kormann, Adrian P. M. | - |
dc.contributor.author | Amazonas, Roberto B. | - |
dc.contributor.author | Oliveira, Monalisa F. Bocchi de | - |
dc.contributor.author | Serpa-Neto, Ary | - |
dc.contributor.author | Falavigna, Maicon | - |
dc.contributor.author | Lopes, Renato D. | - |
dc.contributor.author | Machado, Flávia R. | - |
dc.contributor.author | Berwanger, Otavio | - |
dc.date.accessioned | 2021-07-30T17:29:03Z | - |
dc.date.available | 2021-07-30T17:29:03Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | CAVALCANTI, A. B. et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N. Engl. J. Med., v. 383, n. 21, p. 2041-2052, nov., 2020. Disponível em: https://www.nejm.org/doi/10.1056/NEJMoa2019014?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed. Acesso e: 22 jul. 2021. | pt_BR |
dc.identifier.uri | http://hdl.handle.net/11690/1899 | - |
dc.description.abstract | BACKGROUND Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited. METHODS We conducted a multicenter, randomized, open-label, three-group, controlled trial involving hospitalized patients with suspected or confirmed Covid-19 who were receiving either no supplemental oxygen or a maximum of 4 liters per minute of supplemental oxygen. Patients were randomly assigned in a 1:1:1 ratio to receive standard care, standard care plus hydroxychloroquine at a dose of 400 mg twice daily, or standard care plus hydroxychloroquine at a dose of 400 mg twice daily plus azithromycin at a dose of 500 mg once daily for 7 days. The primary outcome was clinical status at 15 days as assessed with the use of a seven-level ordinal scale (with levels ranging from one to seven and higher scores indicating a worse condition) in the modified intention-to-treat population (patients with a confirmed diagnosis of Covid-19). Safety was also assessed. RESULTS A total of 667 patients underwent randomization; 504 patients had confirmed Covid-19 and were included in the modified intention-to-treat analysis. As compared with standard care, the proportional odds of having a higher score on the seven-point ordinal scale at 15 days was not affected by either hydroxychloroquine alone (odds ratio, 1.21; 95% confidence interval [CI], 0.69 to 2.11; P=1.00) or hydroxychloroquine plus azithromycin (odds ratio, 0.99; 95% CI, 0.57 to 1.73; P=1.00). Prolongation of the corrected QT interval and elevation of liver-enzyme levels were more frequent in patients receiving hydroxychloroquine, alone or with azithromycin, than in those who were not receiving either agent. CONCLUSIONS Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care. (Funded by the Coalition Covid-19 Brazil and EMS Pharma; ClinicalTrials.gov number, NCT04322123.) | pt_BR |
dc.language.iso | en_US | pt_BR |
dc.publisher | Massachusetts Medical Society | pt_BR |
dc.rights | Open Access | en |
dc.subject | Hydroxychloroquine | pt_BR |
dc.subject | Azithromycin | pt_BR |
dc.subject | Mild-to-Moderate Covid-19 | pt_BR |
dc.title | Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 | pt_BR |
dc.type | Artigo | pt_BR |
Aparece nas coleções: | Artigo de Periódico (PPGSDH) |
Arquivos associados a este item:
Arquivo | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Hydroxychloroquine with or without Azithromycin_NEJM.pdf | Open Access | 642,49 kB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.